Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study
dc.contributor.author | Scheinman, Jon | en_US |
dc.contributor.author | Mahan, John D. | en_US |
dc.contributor.author | Alon, Uri S. | en_US |
dc.contributor.author | Norkus, Edward P. | en_US |
dc.contributor.author | Lande, Marc B. | en_US |
dc.contributor.author | Weiss, Robert A. | en_US |
dc.contributor.author | Trachtman, Howard | en_US |
dc.contributor.author | Flynn, Joseph T. | en_US |
dc.contributor.author | Chan, James C. M. | en_US |
dc.date.accessioned | 2006-09-11T19:25:45Z | |
dc.date.available | 2006-09-11T19:25:45Z | |
dc.date.issued | 2003-10 | en_US |
dc.identifier.citation | Chan, James C. M.; Mahan, John D.; Trachtman, Howard; Scheinman, Jon; Flynn, Joseph T.; Alon, Uri S.; Lande, Marc B.; Weiss, Robert A.; Norkus, Edward P.; (2003). "Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study." Pediatric Nephrology 18(10): 1015-1019. <http://hdl.handle.net/2027.42/47819> | en_US |
dc.identifier.issn | 0931-041X | en_US |
dc.identifier.issn | 1432-198X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47819 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12920628&dopt=citation | en_US |
dc.description.abstract | IgA nephropathy is the world's most common primary glomerulonephropathy. Recent evidence in a rat model implicated excessive production of oxygen-free radicals in the pathogenesis and suggested that vitamin E-treatment ameliorated progression. We studied this antioxidant therapy on the glomerular filtration rate (GFR), proteinuria and hematuria in biopsy-proven IgA nephropathy in children. The duration of treatment or placebo was 2 years, with vitamin E treatment consisting of 400 IU/day in children weighing <30 kg, and twice that dose for those >30 kg. We measured GFR at entry, midpoint and exit. At baseline and at 4-month intervals after randomization, urinary protein/creatinine ratios and urinalysis were examined. The mixed model procedure with log transformation was used in data analysis to test treatment difference as well as the potential time effect. Fifty-five patients were randomized and 38 completed at least 1 year of follow-up. At entry, the clinical characteristics were not different between the treatment and placebo groups. There was a trend toward better preservation of GFR in vitamin E-treated versus placebo patients, 127±50 vs. 112±31 ml/min/1.73 m 2 , respectively ( P =0.09). The urinary protein/creatinine ratio was significantly lower in the vitamin E-treated group vs. placebo; 0.24±0.38 vs. 0.61±1.37 ( P <0.013). However, there was no difference in the prevalence of hematuria between the groups. Vitamin E treatment in our study patients was associated with significantly lower proteinuria, but no effect on hematuria. While there was a trend toward stabilization of GFR in the vitamin E-treated patients, long-term treatment and follow-up are needed to determine whether antioxidant therapy is associated with preservation of renal function in IgA nephropathy. | en_US |
dc.format.extent | 151705 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; IPNA | en_US |
dc.subject.other | Medicine | en_US |
dc.subject.other | IgA Nephropathy | en_US |
dc.subject.other | Glomerular Filtration Rate | en_US |
dc.subject.other | Proteinuria | en_US |
dc.subject.other | Vitamin E | en_US |
dc.subject.other | Antioxidant | en_US |
dc.subject.other | Hematuria | en_US |
dc.title | Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan, USA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA | en_US |
dc.contributor.affiliationother | Long Island Jewish Hospital, New Hyde Park, New York, USA | en_US |
dc.contributor.affiliationother | University of Kansas, Kansas City, Kansas, USA | en_US |
dc.contributor.affiliationother | Virginia Commonwealth University, Richmond, Virginia, USA; The Barbara Bush Children's Hospital, Maine Medical Center, 22 Bramhall St., Portland, ME 04102-3175, USA; University of Vermont College of Medicine, Burlington, Vermont, USA | en_US |
dc.contributor.affiliationother | Mercy Children's Hospital, Kansas City, Kansas, USA | en_US |
dc.contributor.affiliationother | University of Rochester, Rochester, New York, USA | en_US |
dc.contributor.affiliationother | Our Lady of Mercy Medical Center, Bronx, New York, USA | en_US |
dc.contributor.affiliationother | New York Medical College, Valhalla, New York, USA | en_US |
dc.contributor.affiliationother | Ohio State University, Columbus, Ohio, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 12920628 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47819/1/467_2003_Article_1205.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00467-003-1205-2 | en_US |
dc.identifier.source | Pediatric Nephrology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Accessibility: If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.